natgillin/translations-raw huggingface dataset:
Read the package leaflet before use for special warnings for immunocompromised humans.
Pred uporabo preberite navodilo za uporabo in posebna opozorila za osebe z zmanjšano imunostjo.
Read the package leaflet before use Intramuscular use
Pred uporabo preberite priloženo navodilo za intramuskularno uporabo
Read the package leaflet before use Intramuscular use
Pred uporabo preberite priloženo navodilo! intramuskularna uporaba
Read the package leaflet before use Intramuscular use
Pred uporabo preberite priloženo navodilo! ntramuskularna uporaba
Read the package leaflet before use Intramuscular use
Pred uporabo preberite priloženo navodilo. intramuskularna uporaba
Read the package leaflet before use Intravenous use
Pred uporabo preberite priloženo navodilo! intravenska uporaba
Read the package leaflet before use Intravenous use
Pred uporabo preberite priloženo navodilo! intravenska uporaba večodmerno
Read the package leaflet before use Intravenous use
Pred uporabo preberite priloženo navodilo. intravensko infundiranje
Read the package leaflet before use Intravenous use after dilution.
Pred uporabo preberite priloženo navodilo! intravenska uporaba po redčenju
Read the package leaflet before use Oral use
Pred uporabo preberite priloženo navodilo Peroralna uporaba
Read the package leaflet before use Oral use
Pred uporabo preberite priloženo navodilo! peroralna uporaba
Read the package leaflet before use Oral use
Pred uporabo preberite priloženo navodilo! za peroralno uporabo
Read the package leaflet before use Oral use
Pred uporabo preberite priloženo navodilo!. peroralna uporaba
Read the package leaflet before use Oral use
Pred uporabo preberite priloženo navodilo. peroralna uporaba
Read the package leaflet before use Oral use.
Pred uporabo preberite priloženo navodilo! peroralna uporaba
Read the package leaflet before use Oral use.
Pred uporabo preberite priloženo navodilo. peroralna uporaba
Read the package leaflet before use Subcutaneous or intravenous use
Pred uporabo natančno preberite priloženo navodilo. za subkutano ali intravensko uporabo
Read the package leaflet before use Subcutaneous or intravenous use
Pred uporabo preberite priloženo navodilo. za subkutano ali intravensko uporabo
Read the package leaflet before use Subcutaneous use
Pred uporabo preberite priloženo navodilo za subkutano uporabo
Read the package leaflet before use Subcutaneous use
Pred uporabo preberite priloženo navodilo! subkutana uporaba
Read the package leaflet before use Subcutaneous use
Pred uporabo preberite priloženo navodilo! za subkutano uporabo
Read the package leaflet before use Subcutaneous use
Pred uporabo preberite priloženo navodilo! za subkutano uporabo.
Read the package leaflet before use Subcutaneous use
Pred uporabo preberite priloženo navodilo. za subkutano uporabo
Read the package leaflet before use Subcutaneous use.
Pred uporabo preberite priloženo navodilo! subkutana uporaba
Read the package leaflet before use.
Natančno preberite navodilo za uporabo.
Read the package leaflet before use.
NAVODILA ZA UPORABO
Read the package leaflet before use.
Odstranjevanje: preberite navodilo za uporabo.
Read the package leaflet before use.
Opozorila in druge pomožne snovi so navedene v navodilu za uporabo.
Read the package leaflet before use.
Preberite priloženo navodilo
Read the package leaflet before use.
Pred infundiranjem razredčite.
Read the package leaflet before use.
Pred uporabo natančno preberite navodila.
Read the package leaflet before use.
Pred uporabo natančno preberite navodilo
Read the package leaflet before use.
Pred uporabo natančno preberite navodilo.
Read the package leaflet before use.
Pred uporabo natančno preberite priloženo navodilo
Read the package leaflet before use.
Pred uporabo peberite navodilo za uporabo.
Read the package leaflet before use.
Pred uporabo preberite navodila za uporabo
Read the package leaflet before use.
Pred uporabo preberite navodilo za uporabo
Read the package leaflet before use.
Pred uporabo preberite navodilo za uporabo. im
Read the package leaflet before use.
Pred uporabo preberite navodilo za uporabo..
Read the package leaflet before use.
Pred uporabo preberite navodilo. za uporabo.
Read the package leaflet before use.
Pred uporabo preberite priloţeno navodilo
Read the package leaflet before use.
Pred uporabo preberite priloženaa navodila.
Read the package leaflet before use.
Pred uporabo preberite priloženo besedilo.
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo za uporabo
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! dermalna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! intramuskularna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! intravitrealna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! nazalna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! okularna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! podjezična uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! transdermalna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! za dermalno uporabo
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! za implantiranje
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo! za nazalno uporabo
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo. dermalna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo. okularna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo. transdermalna uporaba
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo. za dermalno uporabo
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo.Peroralna uporaba.
Read the package leaflet before use.
Pred uporabo preberite proloženo navodilo
Read the package leaflet before use.
Pred uporabo preverite navodilo za uporabo
Read the package leaflet before use.
Pred uporabo preverite navodilo za uporabo.
Read the package leaflet before use.
Za dodatne informacije glejte navodilo za uporabo.
Read the package leaflet before use. (ILP)
Pred uporabo preberite priloženo navodilo! (izolirana perfuzija okončine)
Read the package leaflet before used.
Pred uporabo preberite priloženo navodilo.
Read the Package Leaflet before using Revestive.
Pred uporabo zdravila Revestive preberite navodilo za uporabo.
Read the package leaflet before.
Pred uporabo preberite navodilo za uporabo.
Read the Package Leaflet carefully
Previdno preberite Navodilo za uporabo
Read the package leaflet carefully before use.
Pred uporabo natančno preberite priloženo navodilo
Read the package leaflet carefully before use.
Pred uporabo preberite priloženo navodilo
Read the package leaflet for further information.
Opozorila in druge pomožne snovi so navedene v navodilu za uporabo.
Read the package leaflet for the shelf life after dilution.
Za rok uporabnosti zdravila po razredčitvi glejte navodila za uporabo.
Read the package leaflet for the shelf life after dilution.
Za rok uporabnosti zdravila po razredčitvi glejte navodilo za uporabo.
Read the package leaflet for the shelf life of the reconstituted product
Za informacije o roku uporabnosti rekonstituiranega zdravila preberite navodilo za uporabo.
Read the package leaflet fully before using OptiSet for the first time
Preden prvič uporabite OptiSet, vedno v celoti preberite navodilo za uporabo.
Read the package leaflet fully before using OptiSet for the first time.
Preden prvič uporabite OptiSet, vedno v celoti preberite navodilo za uporabo.
Read the package leaflet.
Preberite navodilo za uporabo.
Read the package leaflets for these medicines for their dosage and directions on ‘how to take’ them.
Za odmerjanje in navodila za jemanje teh zdravil preberite ustrezno navodilo za uporabo, ki je priloženo vsakemu zdravilu.
Read the packaging and ensure you have the dose prescribed by your healthcare professional.
Preberite navodila in se prepri ajte, da imate odmerek, ki vam ga je predpisal zdravstveni delavec.
Read the product information of Nobilis IB Ma5 before use.
Pred uporabo preberite navodilo za uporabo za Nobilis IB Ma5.
Read the Simponi package leaflet carefully before you start using this medicine.
Pred začetkom jemanja natančno preberite priloženo navodilo za zdravilo Simponi.
Read the specific instructions given to you by your doctor, particularly on the effects of Erivedge on unborn babies.
Preberite posebna navodila glede učinkov zdravila Erivedge na nerojene otroke, ki ste jih prejeli s strani vašega zdravnika.
Read the Summary of Product Characteristics before use
Pred uporabo preberite Povzetek glavnih značilnosti zdravila.
Read the Taltz Package Leaflet inside this box to learn more about your medicine.
Preberite Navodilo za uporabo zdravila Taltz v tej škatli, da boste izvedeli več o vašem zdravilu.
Read the User Manual before you start taking Humalog 200 units/ml KwikPen solution for injection and each time you get another Humalog 200 units/ml KwikPen.
Preberite Priročnik za uporabnika, preden začnete jemati zdravilo Humalog 200 enot/ml KwikPen raztopina za injiciranje in vsakokrat, ko dobite nov injekcijski peresnik Humalog 200 enot/ml KwikPen.
Read the User Manual before you start taking Liprolog 200 units/ml KwikPen solution for injection and each time you get another Liprolog 200 units/ml KwikPen.
Preberite Priročnik za uporabnika, preden začnete jemati zdravilo Liprolog 200 enot/ml KwikPen raztopina za injiciranje in vsakokrat, ko dobite nov injekcijski peresnik Liprolog 200 enot/ml KwikPen.
Read the User Manual before you start taking your insulin and each time you get another KwikPen.
Preberite Priročnik za uporabnika, preden začnete jemati insulin in vsakokrat, ko dobite nov peresnik KwikPen.
Read the vaccine package leaflet before use.
Pred uporabo preberite navodilo za uporabo.
Read the “Contraception” section of the package leaflet for ribavirin very carefully.
V navodilih za uporabo za ribavirin natančno preberite poglavje »Kontracepcija«.
Read the “Instructions for Use” for the pen carefully before using Taltz.
Pred uporabo zdravila Taltz natančno preberite „Navodila za uporabo“ peresnika.
Read the “Instructions for Use” for the pen carefully before using Trulicity.
Pred uporabo zdravila Trulicity natančno preberite „Navodila za uporabo“ peresnika.
Read the “Instructions for Use” for the syringe carefully before using Trulicity.
Pred uporabo zdravila Trulicity natančno preberite „Navodila za uporabo“ injekcijske brizge.
Read these instructions all the way through before starting to prepare your medicine.
Preden začnete pripravljati zdravilo, preberite ta navodila v celoti.
Read these instructions carefully before use
Pred uporabo natančno preberite ta navodila
READ THESE INSTRUCTIONS CAREFULLY BEFORE USING NOVOEIGHT.
PRED UPORABO ZDRAVILA NOVOEIGHT NATANČNO PREBERITE TA NAVODILA.
READ THESE INSTRUCTIONS CAREFULLY BEFORE USING NOVOSEVEN
PRED UPORABO ZDRAVILA NOVOSEVEN NATANČNO PREBERITE TA NAVODILA
Read these instructions carefully before using your Lyxumia pen.
Pred uporabo peresnika Lyxumia skrbno preberite ta navodila.
Read these instructions carefully before using your OptiSet.
Preden uporabite OptiSet, natančno preberite ta navodila.
Read these instructions for use before you start using Plegridy and each time you get a new pack.
Preden začnete uporabljati zdravilo Plegridy in vsakič, ko dobite novo pakiranje, preberite to navodilo za uporabo.
Read these messages first
Najprej preberite spodnja opozorila
Read this before you open the package:
Pred odprtjem ovojnine preberite naslednje informacije:
Read this before you start
Pred začetkom uporabe naj bolnik prebere ta navodila
Read this before you start
Pred začetkom uporabe preberite navodila.
Read this guide prior to the preparation and administration of TEPADINA.
Pred pripravo in uporabo zdravila TEPADINA preberite to navodilo.
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke
Readministration to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine
Ponovna uporaba pri bolnikih, pri katerih je bilo treba zdravljenje z njim dokončno ukiniti zaradi hudega izpuščaja, izpuščaja s sočasnimi splošnimi simptomi, preobčutljivostnih reakcij ali klinične oblike hepatitisa zaradi nevirapina.
Readministration to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.
Ponovno dajanje bolnikom, pri katerih je bilo treba zdravljenje z njim dokončno ukiniti zaradi hudega izpuščaja, izpuščaja s sočasnimi splošnimi simptomi, preobčutljivostnih reakcij ali klinične oblike hepatitisa zaradi nevirapina.
Readministration to patients who previously had ASAT or ALAT > 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine (see section 4.4)
Ponovna uporaba pri bolnikih, ki so imeli raven ASAT ali ALAT med prejšnjim zdravljenjem z nevirapinom > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti in pri katerih so se motnje jetrne funkcije ob ponovnem dajanju nevirapina ponovile (glejte poglavje 4.4).
Readministration to patients who previously had ASAT or ALAT > 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine (see section 4.4).
Ponovno dajanje bolnikom, ki so imeli raven ASAT ali ALAT med prejšnjim zdravljenjem z nevirapinom > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti in pri katerih so se motnje jetrne funkcije ob ponovnem dajanju nevirapina ponovile (glejte poglavje 4.4).
Readministration to patients who previously had ASAT or ALAT > 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine (see section 4.4).
Ponovno dajanje bolnikom, ki so imeli raven AST ali ALT med prejšnjim zdravljenjem z nevirapinom > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti in pri katerih so se motnje jetrne funkcije ob ponovnem dajanju nevirapina ponovile (glejte poglavje 4.4).
Ready to add to infusion solution.
Pripravljeno za dodatek raztopini za infundiranje
ready to inject 10 micrograms (mcg)
Pripravljen za injiciranje 10 mikrogramov (µg)
ready to inject 5 micrograms (mcg)
Pripravljen za injiciranje 5 mikrogramov (µg)
ready to pull dose knob out
Pripravljen za izvlečenje gumba za odmerjanja
ready to turn to dose position
Pripravljen za obračanje za nastavitev odmerka
Ready to use
Pripravljeno za uporabo
Ready to use
Pripravljeno za uporabo.
Ready-to-use syringe, containing a single dose of 0.5 ml for injection:
Za uporabo pripravljena napolnjena injekcijska brizga z enkratnim odmerkom 0,5 ml za injiciranje:
Reapplication to the same site within 14 days should be avoided.
Obliža 14 dni ne nameščamo na isto mesto.
Rearranged during transfection (RET) status
Status mutacije RET (Rearranged during transfection)
Reason for discontinuation
razloge za ukinitev,
Reasons for initiation of continuous intra-peritoneal insulin infusion (CIPII) were brittle diabetes in 62.7%, hypoglycaemia in 29.2%, insulin peripheral resistance in 5.0% and hypoglycaemia and brittle diabetes in 3.1%.
Razlogi za uvedbo stalnega intraperitonealnega infundiranja insulina (CIPII – continuous intra-peritoneal insulin infusion) so bili nestabilna sladkorna bolezen ("brittle diabetes") v 62,7 %, hipoglikemije v 29,2 %, periferna odpornost proti insulinu v 5,0 % ter hipoglikemije in nestabilna sladkorna bolezen v 3,1 %.
Reasons for not receiving ERT included the burden of intravenous infusions and difficulties in venous access.
Razloga za nezdravljenje z ERT sta bila breme intravenskega infundiranja in težave z venskim pristopom.
Reassortant influenza virus* (live attenuated) of the following strain**:
Reasortirani virus gripe* (živ, oslabljen) naslednjega seva**:
Reassortant influenza virus* (live attenuated) of the following strain**:
Reasortirani virus gripe* (živ, oslabljen) seva**: A/Vietnam/1203/2004 (H5N1)
Reassortant influenza virus* (live attenuated) of the following strains**:
Novi virus gripe* (živ oslabljen) naslednjih sevov**:
Reattach the chamber to the base.
Komoro potisnite nazaj na podnožje.
RebiDose Instructions for use
Navodila za uporabo peresnika RebiDose
RebiDose is for single use only and should never be reused.
Peresnik RebiDose je namenjen samo za enkratno uporabo, zato ga ne smete nikoli ponovno uporabiti.
RebiDose.
RebiDose
Rebif 22 mcg solution for injection
Rebif 22 μg raztopina za injiciranje
Rebif 22 mcg/0.5 mL solution for injection
Rebif 22 μg/0,5 ml raztopina za injiciranje
Rebif 22 micrograms is available as a package of 1, 3 or 12 syringes.
Rebif 22 mikrogramov je na voljo v pakiranju po 1, 3 ali 12 injekcijskih brizg.
Rebif 22 micrograms solution for injection
Rebif 22 mikrogramov raztopina za injiciranje
Rebif 22 micrograms solution for injection in pre-filled pen
Rebif 22 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku
Rebif 22 micrograms solution for injection in pre-filled pen Interferon beta-1a
Rebif 22 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku interferon beta-1a
Rebif 22 micrograms solution for injection in pre-filled syringe
Rebif 22 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi
Rebif 22 micrograms solution for injection in pre-filled syringe Interferon beta-1a
Rebif 22 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi interferon beta-1a
Rebif 22 micrograms/0.5 mL solution for injection in cartridge
Rebif 22 mikrogramov/0,5 ml raztopina za injiciranje v vložku
Rebif 22 micrograms/0.5 mL solution for injection in cartridge Interferon beta-1a
Rebif 22 mikrogramov/0,5 ml raztopina za injiciranje v vložku. interferon beta-1a
Rebif 44 mcg solution for injection
Rebif 44 μg raztopina za injiciranje
Rebif 44 mcg/0.5 mL solution for injection
Rebif 44 μg/0,5 ml raztopina za injiciranje
Rebif 44 micrograms is available as a package of 1, 3 or 12 syringes.
Rebif 44 mikrogramov je na voljo v pakiranju po 1, 3 ali 12 injekcijskih brizg.
Rebif 44 micrograms solution for injection
Rebif 44 mikrogramov raztopina za injiciranje
Rebif 44 micrograms solution for injection in pre-filled pen
Rebif 44 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku
Rebif 44 micrograms solution for injection in pre-filled pen Interferon beta-1a
Rebif 44 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku interferon beta-1a
Rebif 44 micrograms solution for injection in pre-filled syringe
Rebif 44 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi
Rebif 44 micrograms solution for injection in pre-filled syringe Interferon beta-1a
Rebif 44 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi interferon beta-1a
Rebif 44 micrograms/0.5 mL solution for injection in cartridge
Rebif 44 mikrogramov/0,5 ml raztopina za injiciranje v vložku
Rebif 44 micrograms/0.5 mL solution for injection in cartridge Interferon beta-1a
Rebif 44 mikrogramov/0,5 ml raztopina za injiciranje v vložku interferon beta-1a
Rebif 8.8 mcg solution for injection
Rebif 8,8 μg raztopina za injiciranje
Rebif 8.8 mcg/0.1 mL Rebif 22 mcg/0.25 mL Solution for injection
Rebif 8,8 μg/0,1 ml Rebif 22 μg/0,25 ml raztopina za injiciranje
Rebif 8.8 micrograms and Rebif 22 micrograms are supplied in an initiation pack that is intended for use during the initial 4 weeks of treatment, during which a gradual increase in Rebif dose is recommended.
Rebif 8,8 mikrogramov in Rebif 22 mikrogramov sta na voljo v začetnem pakiranju, ki je namenjen za uporabo v prvih 4 tednih zdravljenja, ko se priporoča postopno povečevanje odmerka zdravila Rebif.
Rebif 8.8 micrograms is a solution for injection in a pre-filled pen for self-administration.
Rebif 8,8 mikrogramov je raztopina za injiciranje v napolnjenem injekcijskem peresniku za samoinjiciranje.
Rebif 8.8 micrograms is a solution for injection in a pre-filled syringe with a fixed needle for self-administration.
Rebif 8,8 mikrogramov je raztopina za injiciranje v napolnjeni injekcijski brizgi s pritrjeno iglo za samoinjiciranje.
Rebif 8.8 micrograms solution for injection
Rebif 8,8 mikrogramov raztopina za injiciranje
Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen
Rebif 8,8 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Rebif 22 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku
Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen Interferon beta-1a
Rebif 8,8 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Rebif 22 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku interferon beta-1a
Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe
Rebif 8,8 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Rebif 22 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi
Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe Interferon beta-1a
Rebif 8,8 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Rebif 22 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi interferon beta-1a
Rebif 8.8 micrograms/0.1 mL solution for injection in cartridge Rebif 22 micrograms/0.25 mL solution for injection in cartridge
Rebif 8,8 mikrogramov/0,1 ml raztopina za injiciranje v vložku Rebif 22 mikrogramov/0,25 ml raztopina za injiciranje v vložku
Rebif 8.8 micrograms/0.1 mL solution for injection in cartridge Rebif 22 micrograms/0.25 mL solution for injection in cartridge Interferon beta-1a
Rebif 8,8 mikrogramov/0,1 ml raztopina za injiciranje v vložku Rebif 22 mikrogramov/0,25 ml raztopina za injiciranje v vložku interferon beta-1a
Rebif can also be used in patients who have had a single attack of demyelination (where the protective sheath around nerves is damaged) accompanied by inflammation.
Zdravilo Rebif se lahko uporablja tudi pri bolnikih, ki so imeli samo en napad demielinazicije (poškodbo zaščitnega ovoja okoli živca), ki ga spremlja vnetje.
Rebif has also been compared with placebo in 515 patients who had experienced a single attack of demyelination.
Zdravilo Rebif so primerjali tudi s placebom pri 515 bolnikih z enim samim napadom demielinizacije.
Rebif has also been studied in patients with secondary progressive MS.
Zdravilo Rebif so proučevali tudi pri bolnikih s sekundarno progresivno multiplo sklerozo.
Rebif has been studied in 560 patients with relapsing MS.
Zdravilo Rebif so proučevali pri 560 bolnikih z multiplo sklerozo z zagoni.
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis and should not be used in these patients.
Zdravilo Rebif še ni bilo raziskano pri bolnikih s primarno progresivno multiplo sklerozo, zato se ga pri teh bolnikih ne sme uporabljati.
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in these patients.
Uporaba zdravila Rebif pri bolnikih s primarno progresivno multiplo sklerozo še ni raziskana, zato se zdravila Rebif pri teh bolnikih ne sme uporabljati.
Rebif is a solution for injection in prefilled syringes, prefilled pens and cartridges.
Zdravilo Rebif je raztopina za injiciranje v napolnjenih injekcijskih brizgah, napolnjenih peresnikih in vložkih.
Rebif is available in packs of 1, 3 and 12 pre-filled syringes.
Rebif je na voljo v pakiranju z 1, 3 ali 12 napolnjenimi injekcijskimi brizgami.